[SCHEDULE 13G] Chemomab Therapeutics Ltd. American Depositary Share SEC Filing

Rhea-AI Filing Summary

Schedule 13G filing dated 06/30/2025 shows Morgan Stanley and subsidiary Morgan Stanley & Co. LLC have exceeded the 5 % threshold in Chemomab Therapeutics Ltd. (CMMB).

• Morgan Stanley reports 32,282,680 ordinary shares/ADS, representing 8.4 % of the outstanding class.
• Morgan Stanley & Co. LLC separately holds 28,786,680 shares or 7.5 %.
• Both entities report shared voting and dispositive power; no sole authority is listed.
• Filed under Rule 13d-1(b) as a broker-dealer/holding company, signalling a passive investment rather than a control bid.
• Cover pages classify the parent as “HC, CO” and the subsidiary as “BD, CO.”
• Signatures by authorised signatory Christopher O’Hara are dated 08/07/2025.

The disclosure increases institutional visibility and liquidity for CMMB but contains no operational or strategic changes.

Insights

Securities Analyst

TL;DR Morgan Stanley now owns 8.4 % of CMMB, indicating passive but sizable institutional support.

The 13G shows a combined 32.3 million ADS held, giving Morgan Stanley meaningful exposure while explicitly remaining passive (Rule 13d-1(b)). Shared voting/dispositive powers mean the bank aggregates client positions rather than deploying its own balance sheet, so immediate activism risk is low. Still, the presence of a tier-one broker-dealer can boost trading liquidity and research coverage, potentially narrowing the discount often seen in micro-cap biotech names like Chemomab. Impact is modest until further accumulation or a switch to a 13D occurs.

Corporate Governance Expert

TL;DR Filing is compliance-driven; no governance change, but ownership concentration inches upward.

The filing underscores Chemomab’s dispersed shareholder base: even after this purchase, the largest holder controls only 8.4 %. Because Morgan Stanley reports under passive status, the board retains autonomy, and no poison-pill or control provisions are triggered. However, a single intermediary controlling >5 % can influence proxy outcomes if client shares are voted as a bloc, so management should maintain active investor relations. Overall governance impact remains neutral.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Chemomab Therapeutics Ltd.

(Name of Issuer)

Ordinary Shares / American Depositary Shares

(Title of Class of Securities)

16385C104

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 16385C104

1

Names of Reporting Persons

Morgan Stanley

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 32,282,680.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 32,282,680.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

32,282,680.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

8.4 %

12

Type of Reporting Person (See Instructions)

HC, CO

SCHEDULE 13G

CUSIP No. 16385C104

1

Names of Reporting Persons

Morgan Stanley & Co. LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 28,786,680.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 28,786,680.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

28,786,680.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

7.5 %

12

Type of Reporting Person (See Instructions)

BD, CO

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Chemomab Therapeutics Ltd.
(b)	Address of issuer's principal executive offices: KIRYAT ATIDIM, BUILDING 7, TEL AVIV, L3, 6158002
Item 2.
(a)	Name of person filing: 1: Morgan Stanley 2: Morgan Stanley & Co. LLC
(b)	Address or principal business office or, if none, residence: 1: 1585 Broadway, New York, NY 10036 ;2: 1585 Broadway, New York, NY 10036
(c)	Citizenship: 1: Delaware 2: Delaware
(d)	Title of class of securities: Ordinary Shares / American Depositary Shares
(e)	CUSIP No.: 16385C104
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See the response(s) to Item 9 on the attached cover page(s).
(b)	Percent of class: 8.4 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See the response(s) to Item 5 on the attached cover page(s).
	(ii) Shared power to vote or to direct the vote: See the response(s) to Item 6 on the attached cover page(s).
	(iii) Sole power to dispose or to direct the disposition of: See the response(s) to Item 7 on the attached cover page(s).
	(iv) Shared power to dispose or to direct the disposition of: See the response(s) to Item 8 on the attached cover page(s).
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. See Exhibit 99.2
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. * In Accordance with the Securities and Exchange Commission Release No. 34-39538 (January 12, 1998) (the "Release"), this filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by certain operating units (collectively, the "MS Reporting Units") of Morgan Stanley and its subsidiaries and affiliates (collectively, "MS"). This filing does not reflect securities, if any, beneficially owned by any operating units of MS whose ownership of securities is disaggregated from that of the MS Reporting Units in accordance with the Release.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Morgan Stanley

Signature:	Christopher O'Hara
Name/Title:	Authorized Signatory, Morgan Stanley
Date:	08/07/2025

Morgan Stanley & Co. LLC

Signature:	Christopher O'Hara
Name/Title:	Authorized Signatory, Morgan Stanley & Co. LLC
Date:	08/07/2025

Exhibit Information

EXHIBIT NO. EXHIBITS ------------------ ------------------------------------ 99.1 Joint Filing Agreement 99.2 Item 7 Information * Attention. Intentional misstatements or omissions of fact constitute federal criminal violations (see 18 U.S.C. 1001).